Search
Displaying 211–220 of 651 for “retinal diseases”
-
Opus Genetics to Launch Gene Therapy Clinical Trial for LCA5 Patients
Research NewsThe LCA5 gene therapy will be the first emerging Opus treatment to move into a human study
-
Research News
The emerging therapy is designed to restore vision for people with advanced retinal degenerative diseases
-
Biologist and Father Dedicated to Daughter’s Cure
Beacon StoriesAfter Allison’s diagnosis with Usher syndrome type 3, her dad, Jeff Libby, wanted to do everything he could to find her a cure. As a biologist, Jeff started searching for organizations researching blinding diseases like Allison’s, and he found the Foundation Fighting Blindness.
-
jCyte Enters into Licensing Agreement with Santen Pharmaceutical for Cell Therapy
Research NewsEmerging treatment designed to preserve vision for people with RP and related conditions
-
Beacon Stories My Retina Tracker Patient Stories
Braydon was diagnosed with an inherited retinal disease at only two years old. Eight years later, after his mom enrolled him in the My Retina Tracker® Program, Braydon learned his disease was LCA.
-
The Legacy Society is a unique group of Foundation Fighting Blindness members who have made a lasting commitment to finding treatments and cures for blinding retinal diseases by making a gift to the Foundation through a will, trust or by beneficiary designation.
The Legacy Society is a way for the Foundation to recognize this profound contribution to retinal research. A gift of any kind to the Foundation is a wonderful act of compassion and generosity.
-
Legacy Society Home page
-
Dr. Don Zack Honored for Research Contributions by ARVO and the Foundation Fighting Blindness
Research NewsDr. Zack is a member of the Foundation’s Scientific Advisory Board and chairs its Cellular Molecular Mechanisms of Disease study section.
-
Ophthotech to Boost Development of Gene Therapy for Best Disease
Research NewsOphthotech Corporation, a biopharmaceutical company focused on the development of therapies for orphan retinal diseases and age-related macular degeneration, has announced an evolving, commercial partnership with the University of Pennsylvania and University of Florida to develop a gene therapy for Best disease caused by BEST1 mutations.
